<DOC>
	<DOCNO>NCT01710228</DOCNO>
	<brief_summary>This study do determine difference natalizumab therapy follow two different withdrawal strategy use Glatiramer Acetate ( GA ) treatment paradigm prevent clinical relapse marker disease activity patient diagnose Multiple Sclerosis ( MS ) . We hypothesize GA plus corticosteroid versus GA alone prevent reduce re-occurrence MS disease activity discontinuation natalizumab 12 month period . We hypothesize natalizumab therapy follow GA treatment allow reconstitution peripheral CNS immune homeostasis . Primary objective : The primary endpoint annualized relapse rate post randomization month well estimate change natalizumab therapy period entire 12 month . Secondary objective : To determine long take restoration immune homeostasis GA therapy follow discontinuation natalizumab .</brief_summary>
	<brief_title>Alternative Treatment Paradigm Natalizumab Trial</brief_title>
	<detailed_description>This phase IIb , multicenter , double-blinded randomize trial determine effect two GA treatment paradigm prevent re-occurrence disease activity immunological rebound withdrawal natalizumab therapy . Importantly , result trial may apply immunoactive agent . A total 200 patient relapse form multiple sclerosis ( MS ) recruit 20 study site United States Europe . Natalizumab dose 300 mg intravenous ( i.v . ) infusion month give standard care least 9 month prior patient enrol study . One day last infusion natalizumab patient start conversion paradigm Glatiramer Acetate ( GA ) . GA administer daily subcutaneous ( s.c. ) dose 20 mg. On day 1 , 2 month patient GA therapy , patient randomize treat methylprednisolone methylprednisolone placebo oral dose 192 mg/day po 5 consecutive day per month duration study . Both Natalizumab Glatiramer Acetate ( GA ) approve FDA treat relapse remit multiple sclerosis . Natalizumab give study medication . Part inclusion criterion patient already receive Natalizumab standard care . Natalizumab randomization provide patient ' medical insurance . Glatiramer acetate ( GA ) randomization till end study ( 12 month ) provide patient ' medical insurance . Teva Pharmaceuticals manufacturer methylprednisolone methylprednisolone placebo 24-mg tablet , look identical . Treatment Arms During 1 month screen period ( month -1 ) , inclusion exclusion criterion verify , subject enrol GA portion follow registration web-based data entry system month 3 , randomly assign treatment stratify accord study site vary block size One day last natalizumab infusion ( month 0 ) , 200 Patients natalizumab therapy start GA. On day 1 month 3 , subject randomize 1:1 receive either : 1 . Methylprednisolone placebo ( `` GA &amp; PL '' ) 2 . Methylprednisolone ( `` GA &amp; MP '' ) addition GA therapy . Randomization two treatment arm occur via random number generator centralize data entry system check eligibility prior initiate randomization prevent inappropriate inclusion . Study Endpoints : 1 . The primary endpoint annualized relapse rate . 2 . A key secondary endpoint percentage relapse-free patient 12 month . 3 . Other secondary outcome rate early relapse rebound ( assessed 200 patient prior randomization ) , number new GD+ lesion MRI 12 month treatment period , defined period follow first infusion ( month 0 ) 6 month 12 month randomization , annualized relapse rate , progression neurological assess change EDSS . 4 . Other MRI outcome include cumulative combined unique activity ( CUA ) ( new enlarge T2 lesion enhance lesion ) . 5 . Another secondary endpoint percentage patient appear free disease activity measure clinical relapse , disability progression measure Expanded Disability Status Scale EDSS ) , cumulative combine unique activity ( CUA ) ( new enlarge T2 lesion enhance lesion ) MRI 12 month .</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Age 18 60 year , inclusive . 2 . Diagnosis relapse form MS use revise McDonald Criteria 11 . 3 . Patients fail GA therapy . 4 . EDSS 0 5.5 ( Functional system change cerebral ( mental ) function bowel bladder function use determine EDSS protocol eligibility ) . 5 . No two relapse 12 month prior initiate natalizumab therapy . 6 . A minimum 9 dos natalizumab prior randomization . 7 . Disease control natalizumab treatment demonstrate absence relapse ( relapse 9 month prior randomization ) 8 . Understood sign write informed consent , obtain prior study subject undergoing studyrelated procedure , include screen test . Enrollment patient TOUCHTM program United States America study site long require : According guideline establish Department Health &amp; Human Services , natalizumab currently available special restrict distribution program call TOUCHTM within United States 1 . Known hypersensitivity GA. 2 . Initiation new immunosuppressant treatment subject become protocoleligible ( except corticosteroid ) enrollment concurrent trial unless exception grant follow consideration MS Review Panel . 3 . Patients treat GA natalizumab therapy fail GA therapy . 4 . Subjects history cytopenia consistent diagnosis myelodysplastic syndrome ( MDS ) . 5 . Active hepatitis B hepatitis C infection evidence cirrhosis . 6 . HIV positivity . 7 . Uncontrolled diabetes mellitus define HbA1c &gt; 8 % and/or require intensive management . 8 . Uncontrolled viral , fungal , bacterial infection ( exclude asymptomatic bacteriuria ) . 9 . Any condition , opinion investigator , would jeopardize ability subject tolerate treatment GA. 10 . Prior history malignancy , except localize basal cell squamous skin cancer . Other malignancy subject judge cured administered therapy , head neck cancer , breast cancer , consider individual basis Study 's MS review panel . 11 . Positive pregnancy test inability unwillingness use effective mean birth control . Effective birth control define : 1 . Refraining act vaginal intercourse ( abstinence ) , 2 . Consistent use birth control pill , 3 . Injectable birth control method ( ®DepoProvera , ®Norplant ) , 4 . Tubal sterilization male partner undergone vasectomy , 5 . Placement IUD ( intrauterine device ) 6 . Use , every act intercourse , diaphragm contraceptive jelly and/or condom contraceptive foam . 12 . Presence metallic object implant body would preclude ability subject safely MRI exam . 13 . Psychiatric illness , mental deficiency , cognitive dysfunction make compliance treatment inform consent impossible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>MS</keyword>
	<keyword>Natalizumab</keyword>
	<keyword>copaxone</keyword>
</DOC>